Literature DB >> 18558286

Gain of the EGFR gene located on 7p12 is a frequent and early event in squamous cell carcinoma of the lung.

Ji Un Kang1, Sun Hoe Koo, Kye Chul Kwon, Jong Woo Park, Sung Su Jung.   

Abstract

Identification of molecular alterations in biological fluids has been proposed as a powerful tool for cancer diagnosis. The purpose of this study was to identify cells that carry chromosomal alterations indicative of malignancy-specifically, gains in the loci 5p15.2 (D5S23, D5S721), 6p11 approximately q11, 7p12 (EGFR), and 8q24.12 approximately q24.13 (MYC)-for the detection of lung cancer using induced sputum. The overall sensitivity of the multicolor fluorescence in situ hybridization (FISH) assay from 52 lung cancer patients was 71% and the specificity was 100% (15 of 15). The most frequently detected gains were at 7p12 (EGFR) in 17 of 24 completely resectable early-stage (II+IIIA) non-small cell lung cancers (NSCLC) (71%). There was a statistically significant increase in the proportion of cases with gains of EGFR in squamous cell carcinomas (SCC), compared with adenocarcinomas (AC) (82 vs. 43%, respectively; P = 0.017), and a higher average EGFR gene copy number in the SCCs than in the ACs (5.04 vs. 3.78, respectively; P = 0.013) in 41 NSCLCs. Conversely, a gain at the 6p11 approximately q11 and 8q24.12 approximately q24.13 (MYC) regions appears to have a higher frequency of gain in the ACs (71 and 86%, respectively) than in the SCCs (48 and 56%, respectively). The results of this study showed the potential utility of the LAVysion FISH assay for the detection of lung cancer by a noninvasive technique based on the analysis of genetic alterations of induced sputum. Defining abnormalities in sputum specimens as FISH aneusomy may be a possible diagnostic method for the early detection of lung cancer in screening of high-risk populations and monitoring for recurrence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558286     DOI: 10.1016/j.cancergencyto.2008.03.002

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.

Authors:  Anna E Barón; Severine Kako; William J Feser; Heather Malinowski; Daniel Merrick; Kavita Garg; Stephen Malkoski; Shannon Pretzel; Jill M Siegfried; Wilbur A Franklin; York Miller; Holly J Wolf; Marileila Varella-Garcia
Journal:  J Thorac Oncol       Date:  2017-06-19       Impact factor: 15.609

2.  Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.

Authors:  Mohammed Taoudi Benchekroun; Pierre Saintigny; Sufi M Thomas; Adel K El-Naggar; Vassiliki Papadimitrakopoulou; Hening Ren; Wenhua Lang; You-Hong Fan; Jianhua Huang; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Faye M Johnson; Jennifer R Grandis; Li Mao
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-22

3.  Genetically abnormal circulating cells in lung cancer patients: an antigen-independent fluorescence in situ hybridization-based case-control study.

Authors:  Ruth L Katz; Weigong He; Abha Khanna; Ricardo L Fernandez; Tanweer M Zaidi; Matthew Krebs; Nancy P Caraway; Hua-Zhong Zhang; Feng Jiang; Margaret R Spitz; David P Blowers; Carlos A Jimenez; Reza J Mehran; Stephen G Swisher; Jack A Roth; Jeffrey S Morris; Carol J Etzel; Randa El-Zein
Journal:  Clin Cancer Res       Date:  2010-07-22       Impact factor: 12.531

4.  Estimating the order of mutations during tumorigenesis from tumor genome sequencing data.

Authors:  Ahrim Youn; Richard Simon
Journal:  Bioinformatics       Date:  2012-04-06       Impact factor: 6.937

5.  Prognostic Impact of EGFR Amplification and Visceral Pleural Invasion in Early Stage Pulmonary Squamous Cell Carcinomas Patients after Surgical Resection of Primary Tumor.

Authors:  Luís Miguel Chinchilla-Tábora; José María Sayagués; Idalia González-Morais; Marta Rodríguez; María Dolores Ludeña
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

Review 6.  Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs.

Authors:  Beata Zahorowska; Philip J Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-17       Impact factor: 4.553

7.  Immunohistochemical expression of EGFR in oral leukoplakia: association with clinicopathological features and cellular proliferation.

Authors:  Daniela-Cotta Ribeiro; Frederico-Omar Gleber-Netto; Sílvia-Ferreira Sousa; Vanessa-de-Fátima Bernardes; Mauro-Henrique-Nogueira Guimarães-Abreu; Maria-Cássia-Ferreira Aguiar
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-09-01

8.  Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer.

Authors:  Yen-Tsung Huang; Xihong Lin; Lucian R Chirieac; Ray McGovern; John C Wain; Rebecca S Heist; Vidar Skaug; Shanbeh Zienolddiny; Aage Haugen; Li Su; David C Christiani
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

9.  NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.

Authors:  Elena Galvani; Jing Sun; Leticia G Leon; Rocco Sciarrillo; Ravi S Narayan; Robert Tjin Tham Sjin; Kwangho Lee; Kadoaki Ohashi; Daniëlle A M Heideman; Roberta R Alfieri; Guus J Heynen; René Bernards; Egbert F Smit; William Pao; Godefridus J Peters; Elisa Giovannetti
Journal:  Oncotarget       Date:  2015-12-15

10.  Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung.

Authors:  Ji Un Kang; Sun Hoe Koo; Kye Chul Kwon; Jong Woo Park; Jin Man Kim
Journal:  BMC Cancer       Date:  2009-07-16       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.